31.60
0.01 (0.03%)
| Penutupan Terdahulu | 31.59 |
| Buka | 31.65 |
| Jumlah Dagangan | 460,635 |
| Purata Dagangan (3B) | 303,387 |
| Modal Pasaran | 2,208,199,424 |
| Harga / Buku (P/B) | 8.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2026 |
| EPS Cair (TTM) | -3.27 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.33% |
| Nisbah Semasa (MRQ) | 11.10 |
| Aliran Tunai Operasi (OCF TTM) | -134.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -79.65 M |
| Pulangan Atas Aset (ROA TTM) | -31.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -52.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Pharvaris N.V. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.80 |
|
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 6.25% |
| % Dimiliki oleh Institusi | 89.49% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LU PENG | - | 31.46 | -226 | -7,104 |
| MODIG BERNDT | - | 31.54 | -2,291 | -72,258 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,517 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -79,362 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 31.49 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MODIG BERNDT | Pegawai | 15 Jun 2026 | Jual automatik (-) | 2,291 | 31.54 | 72,258 |
| LU PENG | Pegawai | 12 Jun 2026 | Dibuang (-) | 117 | 30.72 | 3,594 |
| LU PENG | Pegawai | 11 Jun 2026 | Dibuang (-) | 109 | 32.20 | 3,510 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |